2.5 million euros for five research teams from Bavaria
. 5 million euros funding for innovative projects in biomedicine The research projects address the topics: Hepatitis-B…
. 5 million euros funding for innovative projects in biomedicine The research projects address the topics: Hepatitis-B…
4SC AG (4SC or "the Company") (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients sufferin…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survi…
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…
Resminostat met the primary endpoint in the RESMAIN study, demonstrating a statistically significant improvement in prog…
4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2023, presenting all material developments up…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…